» Articles » PMID: 14567028

Initiation of a Program in Peritoneal Surface Malignancy

Overview
Date 2003 Oct 22
PMID 14567028
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The initiation of a Program in Peritoneal Malignancy is a long and complex process. The novelty, technically demanding nature and steep learning curve that characterize this treatment strategy calls for a carefully planned, systematic, controlled, and informed introduction is an institution, for which an Institutional Review Board approved protocol is suggested. Commitment of a surgical team and institution, education of other physician, nurses, and ancillary personnel involved in the procedure, safety precaution for patients and health care workers, and proper patient selection are important requirements for initiating the program. This manuscript provides a guide for implementation of this treatment strategy with a minimum of untoward events, reduced apprehension of medical and nursing colleagues, and a maximum benefit for patients.

Citing Articles

Current Opinion and Practice on Peritoneal Carcinomatosis Management: The North African Perspective.

Souadka A, Essangri H, Makni A, Abid M, Ayadi M, Ksantini F Front Surg. 2022; 9:798523.

PMID: 35350143 PMC: 8957835. DOI: 10.3389/fsurg.2022.798523.


Mid-Term Audit of a National Peritoneal Surface Malignancy Program Implementation in a Low Middle Income Country: The Moroccan Experience.

Souadka A, Essangri H, Majbar M, Benkabbou A, Boutayeb S, Amrani L Cancers (Basel). 2021; 13(5).

PMID: 33802609 PMC: 7962020. DOI: 10.3390/cancers13051088.


Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery.

Poskus E, Strupas K, Gushchin V, Sugarbaker P Viszeralmedizin. 2015; 30(5):353-9.

PMID: 26535046 PMC: 4571719. DOI: 10.1159/000368685.


Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary?.

Lopez-Basave H, Morales-Vasquez F, Mendez-Herrera C, Namendys-Silva S, Luna-Ortiz K, Calderillo-Ruiz G J Oncol. 2014; 2014:307317.

PMID: 24864143 PMC: 4016883. DOI: 10.1155/2014/307317.


[Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion].

Pelz J, Germer C Chirurg. 2013; 84(11):957-61.

PMID: 24218093 DOI: 10.1007/s00104-013-2513-0.